Smartwatch tool predicts Parkinson’s disease up to 7 years before onset
By
Aaron Dorman
Jul 11, 2023
Data from a smart watch could help predict Parkinson’s disease up to seven years before symptoms begin occurring, a new study shows.
FDA gives full approval to Alzheimer’s disease drug Leqembi
Jul 06, 2023
Although Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds.
Number of teeth, periodontitis in older adults linked to hippocampal atrophy
Jul 06, 2023
A qualitative interaction was seen between the number of teeth present and the mean periodontal probing depth for symmetric percentage change in left hippocampus.
Firearm-owning veterans receptive to safety discussions in routine care
Jul 03, 2023
The findings are based on a survey encompassing six clinical contexts involving heightened risk for firearm injury.
Intranasal insulin may have pro-cognitive benefits
Jun 30, 2023
Improvement in global cognition was seen for patients with Alzheimer’s disease/mild cognitive impairment, but no effects were seen for healthy individuals or other patient populations.
Package of bills targets memory care services, staffing agency regulation
By
Kimberly Bonvissuto
Jun 06, 2023
Delaware lawmakers took the recommendations from a recently released long-term care task force report to heart in introducing a package of bills that target dementia care and temporary staffing agency...
Rosalynn Carter’s dementia news ‘will increase important conversations’ about disease, family hopes
By
Kimberly Bonvissuto
May 31, 2023
Sharing the news that former first lady Rosalynn Carter has dementia will “increase important conversations at kitchen tables and in doctor’s offices around the country,” the Carter family hoped...
Diabetes plus tooth loss tied to worse cognition
Mar 24, 2023
Faster cognitive decline was seen for older adults with both conditions.
Social isolation tied to wide variety of dementia risk factors
Feb 02, 2023
Social isolation may be a modifiable risk factor for preventing Alzheimer’s disease-related dementias, authors say.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.